Summit Therapeutics/$SMMT
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Summit Therapeutics
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.
- Ticker
- $SMMT
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 265
- Headquarters
- Miami, United States
- Website
- www.smmttx.com
SMMT Metrics
BasicAdvanced
$14B
-
-$1.12
-1.26
-
Price and volume
Market cap
$14B
Beta
-1.26
52-week high
$29.23
52-week low
$12.07
Average daily volume
7M
Financial strength
Current ratio
6.958
Quick ratio
6.669
Long term debt to equity
0.027
Total debt to equity
0.032
Profitability
EBITDA (TTM)
-874.67
Management effectiveness
Return on assets (TTM)
-101.61%
Return on equity (TTM)
-192.50%
Valuation
Price to book
21.62
Price to tangible book (TTM)
21.68
Price to free cash flow (TTM)
-28.6
Free cash flow yield (TTM)
-3.50%
Free cash flow per share (TTM)
-0.6
Growth
Earnings per share change (TTM)
10.27%
3-year earnings per share growth (CAGR)
-8.26%
What the Analysts think about SMMT
Analyst ratings (Buy, Hold, Sell) for Summit Therapeutics stock.
Analyst projections of the future price of Summit Therapeutics stock.
Bulls say / Bears say
In Akeso’s Phase III HARMONi-2 trial, ivonescimab improved overall survival versus pembrolizumab in PD-L1-positive lung cancer: median survival was 30.8 months versus 22.6 months, with a statistically significant hazard ratio of 0.73. This strengthens the case that the drug could compete beyond its initial proposed use. (Business Wire)
Ivonescimab’s potential may extend beyond lung cancer: Akeso reported that Phase III HARMONi-GI1 met its overall-survival, progression-free-survival and response-rate endpoints in advanced biliary tract cancer. A broader set of indications could support a larger opportunity if results translate into Summit’s markets. (Business Wire)
AstraZeneca agreed to invest $2 billion in Summit and collaborate on trials combining ivonescimab with its cancer medicines. The investment adds substantial funding, while the partnership may help broaden the drug’s development programme. (Summit Therapeutics)
The November FDA decision remains a major uncertainty: the original HARMONi analysis missed statistical significance for overall survival, and the later Western subgroup estimate still had a confidence interval that includes no benefit. That leaves Summit’s first potential US launch exposed to regulatory risk. (BioSpace, BioTech Distilled)
The survival benefit may come with added toxicity: in HARMONi-2, serious treatment-related adverse events occurred in 29.9% of ivonescimab patients versus 21.6% on pembrolizumab. Higher serious-event rates could complicate treatment decisions and the drug’s eventual uptake. (StockTitan)
Summit has already relied on share sales to fund development, raising $230.8 million gross through its at-the-market facility in the second quarter and another $68.4 million after quarter-end. Further funding needs could mean more dilution before the company has product revenue. (Summit Therapeutics)
Data summarised monthly by Lightyear AI. Last updated on 30 Sept 2026.
SMMT Financial Performance
Revenues and expenses
SMMT Earnings Performance
Company profitability
Upcoming events
No upcoming events
SMMT News
AllArticlesVideos
Summit Therapeutics Announces Clinical Trial Collaboration with AstraZeneca and Daiichi Sankyo to Evaluate Ivonescimab in Combination with TROP2-Directed ADC Datroway
Business Wire1 week ago
Daiichi Sankyo and AstraZeneca Enter into Clinical Trial Collaboration with Summit Therapeutics to Evaluate Datroway® in Combination with Ivonescimab Across Multiple Tumor Types
Business Wire1 week ago
AstraZeneca Invests in Summit Therapeutics after Year of Speculation
Benzinga1 week ago
Funds containing SMMT
AllUSDGBPEUR
Fund name | Fund size | $SMMT weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.97% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.97% |
iShares MSCI World Small Cap$WSML | $9B | 0.02% |
iShares MSCI World Small Cap€IUSN | €7.8B | 0.02% |
iShares MSCI World Small Cap£WLDS | £6.7B | 0.02% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.